Report cover image

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published May 31, 2022
Length 37 Pages
SKU # GMD17226499

Description

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Gamma-aminobutyric acid A receptor, alpha 2 or GABRA2 is a protein encoded by the GABRA2 gene. GABRA2 are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System and Dermatology which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome), Panic Disorders and Pruritus.

The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 - Drugs In Development, 2022, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2)
  • The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

37 Pages
Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Companies Involved in Therapeutics Development
Baergic Bio Inc
Cerevel Therapeutics Holdings Inc
Engrail Therapeutics Inc
Saniona AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Drug Profiles
BAER-101 – Drug Profile
darigabat – Drug Profile
NCT-10004 – Drug Profile
SAN-711 – Drug Profile
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia – Drug Profile
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) – Product Development Milestones
Featured News & Press Releases
Mar 24, 2022: Saniona initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial
Feb 15, 2022: Cerevel Therapeutics announces positive topline results for Darigabat in phase 1 clinical trial in acute anxiety
Feb 10, 2022: Saniona initiates multiple ascending dose stage of SAN711 phase 1 clinical trial
Aug 31, 2021: BioStock: Saniona’s clinical and regulatory progress during H1
Jun 30, 2021: Saniona initiates phase 1 clinical trial of SAN711
Jun 08, 2021: Saniona to present preclinical data on SAN711 at the 7th Congress of the European Academy of Neurology
Jan 28, 2021: Cerevel Therapeutics hosts Inaugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs
Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigational therapy in development for the treatment of Epilepsy
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment
Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain
Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004
Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indication, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Number of Products by Stage and Mechanism of Actions, 2022
Table 7: Number of Products by Stage and Route of Administration, 2022
Table 8: Number of Products by Stage and Molecule Type, 2022
Table 9: Pipeline by Baergic Bio Inc, 2022
Table 10: Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Table 11: Pipeline by Engrail Therapeutics Inc, 2022
Table 12: Pipeline by Saniona AB, 2022
Table 13: Dormant Projects, 2022
Table 14: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Stage and Route of Administration, 2022
Figure 6: Number of Products by Stage and Molecule Type, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us